SCHEMBL5738428

SCHEMBL5738428

Fc1ccc(-c2cn3cc(Cl)cc(Cl)c3n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.70
NPC1 O15118 8/20 0.70
RAB9A P51151 8/20 0.70
NFKB1 P19838 5/20 0.70
NFKB2 Q00653 5/20 0.70
RELA Q04206 5/20 0.70
LMNA P02545 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70
RECQL P46063 1/20 0.70
MAPT P10636 4/20 0.52
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
TP53 P04637 4/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A3 P47895 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13325722 0.88 NPC1 (0.58) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL31071673 0.85 NPC1 (0.67) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL13325728 0.84 RAB9A (0.51) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL1691698 0.84 ALDH1A1 (0.52) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL13325718 0.84 NPC1 (0.63) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL31071674 0.82 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3030499 0.81 NPC1 (0.70) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL5739105 0.78 RAB9A (0.68) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL22615018 0.75 RAB9A (0.51) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL38665964 0.75 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401836-B1 IMIDAZO¬1,2-A|PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS SMITHKLINE BEECHAM CORP (US) 2006-08-23 EP disclosed
US-20060167252-A1 Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections GUDMUNDSSON KRISTJAN 2006-07-27 US disclosed
US-20050228004-A1 Imidazo'1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections SMITHKLINE BEECHAM CORPORATION 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228004-A1 Imidazo'1,2-a!pyridine derivatives for the prophylaxis and treatment of herpes viral infections TPMT, IRF3, ZC3HAV1 SMN1; SMN2 3453/4885NPC1 1119/4885RAB9A 1784/4885
US-20060167252-A1 Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections IRF3, IFNAR1, IL2 SMN1; SMN2 3601/4885NPC1 1030/4885RAB9A 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.